CONTROVERSY REGARDING THE USE OF THE VACCINE AGAINST HUMAN PAPILLOMAVIRUS
DOI:
https://doi.org/10.31052/1853.1180.v19.n3.13074Keywords:
Human Papillomavirus, Human Papillomavirus Vaccine, Cervical neoplasmAbstract
The Human Papillomavirus (HPV) vaccine is presented as a primary preventive measure of cervical cancer (CC), the second cause of women deaths in the world. This vaccine generates such social dichotomy that makes us consider whether its administration is really necessary. The possible causes of this controversy are developed in this article, with the aim of helping to make an informed decision about its administration. Available vaccines are reviewed, as well as use recommendations and controversy regarding effectiveness, security, required doses, prevention efficiency and people’s participation. HPV vaccines offer a promising approach to prevent cervical cancer and conditions associated with these viruses, but they do not replace other prevention strategies since they do not protect against all HPV types.
Downloads
References
1. Organización Mundial para la Salud. Estrategia Mundial de Salud de las Mujeres y los Niños. Nueva York; 2010.
2. Organización Panamericana de la Salud. Organización Mundial de la Salud. Resolución CD 48. R10. Estrategia y Plan de Acción Regionales sobre la Prevención y el Control del Cáncer Cervicouterino. 2008 Oct 10.
3. Ministerio de Salud de la Nación Argentina. Vacuna contra el virus del papiloma humano (VPH). 2011. p.5.
4. Ministerio de Salud de la Nación Argentina. Instituto Nacional del Cáncer. Estadística. El cáncer en cifras [se-rie online]. 2014 [citado en 2014 Nov 12]. Disponible en: http://www.msal.gov.ar/inc/index.php/acerca-del-cancer/estadisticas#panel-4
5. Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud de EE.UU. Pruebas de Papanicolaou y del virus del papiloma humano (VPH) [serie online]. 2014 Sept 09 [citado en 2014 Oct 02]. Disponible en: http://www.cancer.gov/espanol/recursos/hojas-informativas/deteccion-diagnostico/papanicolaou-respuestas
6. Servicio Madrileño de Salud. Notas Farmacoterapéuticas. Vacunas frente al virus del papiloma humano. 2008;15(5):17-8.
7. Centro Andaluz de Información de Medicamentos. Vacuna frente al virus del papiloma humano. Boletín Terapéutico Andaluz. 2007;23(4).
8. Dunne E, Unger E, Stenrberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-9.
9. Ministerio de Salud de la Nación Argentina. Vacuna contra el Virus del Papiloma Humano (VPH). 2011. p. 18-9.
10. Nielsen AR, Hayney MS. Human Papillomavirus: A Brief Overview and Recommendations for Pharmacists. J Am Pharm Assoc. 2014:54(5):558-61.
11. Katki HA, Kinney �K, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for hu-Katki HA, Kinney �K, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for hu-man papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. [2011 Jul;12(7):663-72]. Lancet Oncol. 2011 Aug;12(8):722.
12. �orld Health Organization. Human Papilomavirus (HPV) Vaccine. Backgrown Paper [serie online]. 2008 Sept [citado en 2014 Jul 07]. Disponible en: http://www.who.int/immunization/documents/Human.
13. De Martel C, Ferlay J, Franceschini S, et al. Global burden of cancer attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 2012;13:607-15.
14. Ministerio de Salud de la Nación Argentina. Instituto Nacional del Cáncer. Estadística [serie online] 2014 [citado en 2014
99Revista de Salud Pública, (XIX) 3:91-103 Diciembre 2015Controversias en torno a la utilización de la vacuna... / Silvana María Quiroga, Elena María Vega, Marta Stella Maris Fungo, Sonia Andrea Naeko UemaNov 12]. Disponible en: http://www.msal.gov.ar/inc/index.php/acerca-del-cancer/estadisticas#panel-4.
15. Ciapponi A, Bardach A, Glujovsky D, et al. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PloS One. 2011;6(10):e25493.
16. Memarzadeh S, Berek JS. Neoplasias ginecológicas malignas. Cáncer de cuello uterino. En Casciato DA, Territo MC, editores. Manual de oncología clínica. 7° ed. Philadelphia, �olters Kluwer Health SA., Lippincott �illiams & �ilkins; 2012 p. 322.
17. Antilla A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 european countries. Br J Cancer. 2004;91:937-41.
18. Food and Drug Administration. FDA news release. FDA approves first human papillomavirus test for primary cervical screening [serie online]. 2014 Ab 24 [citado en 2014 Jul 24]. Disponible en: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm
19. Bulkmans N�, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for imple-Bulkmans N�, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for imple-mentation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44.102 women. Int J Cancer. 2004 May 20;110(1):94-101.
20. Pontus Nauclear, Alter Ryd, Sven Tornberg, Joakin Dillner. Human Papillomavirus and Pap test to screen for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1589-97.
21. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014;349:g5264.
22. Cancer Network. Urine test �orks for HPV screening [serie online] 2014 Sept 28 [citado en 2014 Oct 12]. Disponible en: http://www.cancernetwork.com/hpv/urine-test-works-hpv-screening
23. International Agency for Research on CancerHandbook of Cancer prevention. Cervical Cancer Screening. 2005;10.
24. Andersson-Ellstrom A, Dillner J, Hagmar. Organisation and results of the cervical cytology screening programme in Brit-Andersson-Ellstrom A, Dillner J, Hagmar. Organisation and results of the cervical cytology screening programme in Brit-ish Columbia, 1955-85. Br Med J (Clin Res Ed). 1988 Apr 2;296(6627):975-8.
25. Centers for Disease Control and Prevention. Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants’ Meeting. Department of Health and Human Services. Atlanta, 2011 Dec.
26. National Cancer Institute. Los virus del papiloma humano y el cáncer [serie online]. 2009 Sept 21 [citado en 2014 Jul 13]. Disponible en: http://www.cancer.gov/espanol/cancer/hijas-informativas/VPHrespuestas
27. �iner RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354(25):2645–54.
28. Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud de EE.UU. Vacunas contra los virus del papiloma humano [serie online]. 2011 Dic 29 [citado en 2014 Oct 29]. Disponible en: http://www.cancer.gov/espanol/recursos/hojas-informativas/prevencion/vacuna-VPH
29. Schiller JT, Davis P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004;2:343-47.
30. Centers for Disease Control and Prevention. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervar-Centers for Disease Control and Prevention. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervar-ix) for Use in Females and Update HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). MM�R. 2010;59(20):626-9.
31. Centers for Disease Control and Prevention. Recommendations on the Use of Quadrivalent Human Papillomavirus Vac-Centers for Disease Control and Prevention. Recommendations on the Use of Quadrivalent Human Papillomavirus Vac-cine in Males-Advisory Committee on Immuninization Practices (ACIP). MM�R. 2011;60(50):1705-8.
32. Ministerio de Salud de la Nación Argentina. Vacuna contra el virus del papiloma humano (VPH). 2011. p.18.
33. Cuschieri K. Should boys receive the human papilomavirus vaccine? BMJ. 2009;339:b4928.
34. Centros para el Control y la Prevención de enfermedades. Información para médicos sobre la vacuna contra el VPH: Hoja informativa [serie online]. 2012 Ago 13 [citado en 2014 Nov 22]. Disponible en: http://www.cdc.gov/std/spanish/stdfact-hpv-vaccine-hcp-s.htm
35. Parkin DM, Almonte M, Bruni I, et al. Burden of HPV infection and related disease in Latin America and Caribbean region. Vaccine. 2008 Aug. 19;26(11):1-15.
36. Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud de EE.UU. Vacunas contra los virus del papiloma humano [serie online]. 2011 Dic 29 [citado en 2014 Oct 29]. Disponible en: http://www.cancer.gov/espanol/recursos/hojas-informativas/prevencion/vacuna-VPH
37. Centers for Disease Control and Prevention. Adult Immunization Schedules [serie online]. 2014 Feb 06 [citado en 2015 Feb 06]. Disponible en: http://www.cdc.gov/vaccines/schedules/hcp/adult.html
38. Gardasil. Ficha técnica o resumen de las características del producto [serie online]. 2014 [citado en 2014 Ago 18]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000703/�C500021142.pdf
39. Cervarix. Ficha técnica o resumen de las características del producto [serie online]. 2010 [citado en 2014 Ago 18]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000721/�C500024632.pdf
40. Gardasil 9. Human Papillomavirus 9-valent Vaccine, Recombinant [serie online]. 2014 [citado en 2015 Mar 15]. Dispo-Gardasil 9. Human Papillomavirus 9-valent Vaccine, Recombinant [serie online]. 2014 [citado en 2015 Mar 15]. Dispo-2014 [citado en 2015 Mar 15]. Dispo-nible en: https://www.merck.com/product/vaccines/home.html
41. Food and Drug Administration. Gardasil (human papilomavirus quadrivalent [types 6, 11, 16 y 18] vaccine, recombi-Food and Drug Administration. Gardasil (human papilomavirus quadrivalent [types 6, 11, 16 y 18] vaccine, recombi-nant): product information and supporting documents [serie online]. 2006 [citado en 2014 Ago 18]. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm
42. Slade BA, Leidel L, Vellozi C. Postlicensure Safety surveillance for Quadrivalent Human Papilomavirus Recombinant Vaccine. JAMA. 2009;302:750-7.
43. Garland SM, Hernandez-Avila M, �heeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quiadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43.
44. Food and Drug Administration. Cervarix [serie online]. 2009 Oct 16 [citado en 2014 Ago 18]. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm
45. Food and Drug Administration. Gardasil 9 [serie online]. 2014 Dec 10 [citado en 2015 Feb 15]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/ComunicadosdePrensa/ucm426591.htm
46. Laucirica R, Tambouret R, Schwartz MR. New FDA approvals of HPV vaccines. PAP/NGC.R Programs review. Cap today [serie online]. 2010 Jan [citado en 2014 Jul 12]. Disponible en: http://www.cap.org/apps
47. Food and Drug Administration. FDA approves new indications for Gardasil to prevent genital warts in men and boys [se-Food and Drug Administration. FDA approves new indications for Gardasil to prevent genital warts in men and boys [se-rie online]. 2009 [citado en 2014 Jul 12]. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Appro-2009 [citado en 2014 Jul 12]. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Appro-vedProducts/UCM094042
48. Medscape. Protect the Next Generation: Recommend the HPV Vaccine [serie online]. 2014 Aug 18 [citado en: 2015 Mar 02]. Disponible en: http://www.medscape.com/viewarticle/829938
49. Medscape. HPV Vaccine Uptake Remains “Unacceptably Low”, CDC Says [serie online]. 2014 Jul 24 [citado en 2015 Mar 02]. Disponible en: http://www.medscape.com/viewarticle/828871
100Revista de Salud Pública, (XIX) 3:91-103 Diciembre 2015Controversias en torno a la utilización de la vacuna... / Silvana María Quiroga, Elena María Vega, Marta Stella Maris Fungo, Sonia Andrea Naeko Uema
50. Centers for Disease Control and Prevention. Cobertura del Papiloma Humano vacunación en adolescentes, 2007-2013, y monitoreo Post licencia. Seguridad de las Vacunas, 2006-2014 [serie online]. 2014 Jul 25 [citado en 2015 Mar 15]. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a3.htm
51. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MM�R. 2011;60.(No. RR-2).
52. Vacuna del virus del papiloma humano para los genotipos 6,11, 16 y 18 (Giardasis). Rev Prescrire. 2007;27(280):89-93. Traducido por Boletín Fármacos 2007;10(5):15.
53. The FUTURE II Study Group. Quadrivalent Vaccine againts Human Papillomavirus to Prevent High-Grade cervical Lesions (FUTURE II) N Engl J Med. 2007 May 10;356(19):1915-27.
54. Pavonen J, Jenkins D, Bosch X, Naud P, Salmeron J, et al for VPH PATRICIA study group. Efficacy of a prophylactic adyuvanted bivalent L1 virus-like-paticle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet. 2007;369:369:2161-70.
55. Azvolinsky A. New HPV Vaccine could prevent 90% of cervical cancers [serie online]. 2014 Oct 06 [citado en 2014 Oct 19]. Disponible en: http://www.cancernetwork.com/cervical-cancer/new-hpv-vaccine-could-prevent-90-percent-cervical-cancers
56. American Cancer Society. Vacunas contra el VPH [serie online]. 2014 Abr 08 [citado en 2014 Oct 02]. Disponible en: http://www.cancer.org/espanol/cancer/queesloquecausaelcancer/infeccionesycancer/fragmentado/virus-del-papiloma-humano-vph-cancer-y-la-vacuna-contra-el-vph-preguntas-frecuentes-are-hpv-vaccines-safe
57. Food and Drug Administration. Gardasil Vaccine Safety. Information from FDA and CDC on Safety of Gardasil Vac-Food and Drug Administration. Gardasil Vaccine Safety. Information from FDA and CDC on Safety of Gardasil Vac-cine [serie online]. 2009 [citado en: 2015 Abr 17]. Disponible en: http://www.fda.gov/BiologicsBloodVaccine/SafetyA-2009 [citado en: 2015 Abr 17]. Disponible en: http://www.fda.gov/BiologicsBloodVaccine/SafetyA-vailability/VaccineSafety/ucm179549.htm.
58. Gee J, Naleway A, Shuj I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279-84.
59. Centers for Disease Control and Prevention. Vaccine Safety. Human Papillomavirus (HPV) Vaccine [serie online]. 2014 Aug 18 [citado en 2014 Oct 02]. Disponible en: http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index.html
60. Institute of Medicine. Adverse Effects of Vaccine: Evidence and Causality [serie online]. 2011 Ago 25 [citado en 2014 Nov 18]. Disponible en: http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx
61. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013. USA. MM�R. 2013;62:591–5.
62. Medscape. Gardasil [serie online]. 2015 Jan [citado en 2015 Mar 15]. Disponible en: http://reference.medscape.com/drug/gardasil-human-papillomavirus-vaccine-quadrivalent-343111
63. Medscape. Cervarix [serie online]. 2014 Jul [citado en 2015 Mar 15]. Disponible en: http://reference.medscape.com/drug/cervarix-human-papillomavirus-vaccine-bivalent-999308
64. Medscape. Gardasil 9 [serie online]. 2015 Jan [citado en 2015 Mar 15]. Disponible en: http://reference.medscape.com/drug/gardasil-9-human-papillomavirus-vaccine-nonavalent-999976
65. Centers for Disease Control and Prevention. Vaccine Safety. Human Papillomavirus (HPV) Vaccine. [serie online]. 2015 Ene 26 [citado en 2015 Mar 02]. Disponible en: http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index.html
66. Medline Plus. Vacuna contra el HPV [serie online]. 2014 Nov 03 [citado en 2015 Mar 02]. Disponible en: http://www.nlm.nih.gov/medlineplus/spanish/ency/article/007436.htm
67. Organización Mundial de la Salud. Nueva guía de la OMS para la prevención y el control del cáncer cervicouterino [se-rie online]. 2014 Dic 03 [citado en 2014 Dic 15]. Disponible en: http://www.who.int/mediacentre/news/releases/2014/preventing-cervical-cancer/es/.
68. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. Journal of the National Cancer Institute. 2011; 103(19):1444–51.
69. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6:1242-50.
70. Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013;208(8):1325-34.
71. Reporte Epidemiológico de Córdoba N° 1540 [serie online]. 2015 Mar 09 [citado en: 2015 Mar 09] Disponible en: http://www.reporteepidemiologico.com/rec-1540/.
72. Einstein MH. Immune response after primary vaccination course: a comparative trial of two HPV prophylactic vac-Einstein MH. Immune response after primary vaccination course: a comparative trial of two HPV prophylactic vac-cines. Progress in the research on HPV vaccination: updates from the 25th International Papillomavirus Conference. 2009. Malmo, Suecia.
73. Meme une vaccination systématique par un Gardasil supposé efficace n’aurait qu’un faible impact sur I’incidence du cáncer du col de I’utérus, selon une modélisation autrchienne. Pharmacritique [serie online]. 2008 [citado en 2014 Oct 18]. Disponible en: http://pharmacritique.20minutes-blogs.fr/archive/2008/07/02/meme-une-vaccination-systema-tique-par-un-gardasil-suppose-ef.html
74. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. Aug 2013;208(3):385–393.
75. Suba EJ, RAAB SS, on behalf of the Viet/American Cervical Cancer Prevention Projet. HPV vaccination: waiting for evidence of effectiveness. Lancet. 2010;375:639-40.
76. Derecho del Paciente en su Relación con los Profesionales e Instituciones de la Salud. Ley 26.529, Honorable Congreso de la Nación, República Argentina (Boletín Oficial, 2009 Nov 19).
77. Declaración de Lisboa de la Asociación Médica Mundial (�MA) sobre los Derechos de los Pacientes. Adoptada por la 34a asamblea Médica Mundial. Lisboa, 1981 Sept-Oct. Enmendada por la 47a Asamblea General. Bali; 1995 Sept.
78. De Protección Integral de los derechos de las Niñas, Niños y Adolescentes. Ley 26.061, Honorable Congreso de la Nación, república Argentina (Boletín oficial 2005 Oct 21).
79. Tealdi JC. Los derechos de los pacientes desde una bioética de los Derechos Humanos. En: Garay OE. Derecho de los pacientes. Buenos Aires: UNESCO, Editores; 2003. p.242-52.
80. Centros para el Control y la Prevención de Enfermedades. Información para las mujeres jóvenes contra el VPH: Hoja informativa [serie online]. 2012 Sept 10 [citado en 2014 Ag 27]. Disponible en: http://www.cdc.gov/std/spanish/vph/STDFact-hpv-vaccine-young-women-s.htm
81. Asociación de Afectadas por la Vacuna del Papiloma. Listado de eventos adversos informados [serie online]. Fecha [citado en 2015 Mar 31]. Disponible en: URL: http://inicio.aavp.es/index.php?option=com_content&view=category&layout=blog&id=40&Itemid=1
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
How to Cite
